CLINICAL TRIALS PROFILE FOR SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

All Clinical Trials for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00103857 ↗	MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2005-03-17	The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).
NCT00337610 ↗	Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-06-01	A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.
NCT00350779 ↗	Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-06-12	A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy.
NCT00395343 ↗	Sitagliptin Added-on to Insulin Study (0431-051)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-12-11	A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.
NCT00420511 ↗	Beta-Cell Function and Sitagliptin Trial (BEST)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2007-01-01	Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). The investigators propose a double-blind, randomized controlled pilot study comparing the effect of sitagliptin (a novel anti-diabetic drug with beta-cell protective potential) versus placebo, on the preservation of beta-cell function over one year in patients with T2DM on metformin, the first-line agent for the treatment of T2DM (ie. the study groups will be (i) sitagliptin and metformin versus (ii) placebo and metformin). This study may demonstrate an important beta-cell protective capacity of sitagliptin. Hypothesis: In patients with T2DM on metformin, treatment with the DPP-IV inhibitor sitagliptin will preserve pancreatic beta-cell function.
NCT00420511 ↗	Beta-Cell Function and Sitagliptin Trial (BEST)	Completed	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Phase 2	2007-01-01	Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). The investigators propose a double-blind, randomized controlled pilot study comparing the effect of sitagliptin (a novel anti-diabetic drug with beta-cell protective potential) versus placebo, on the preservation of beta-cell function over one year in patients with T2DM on metformin, the first-line agent for the treatment of T2DM (ie. the study groups will be (i) sitagliptin and metformin versus (ii) placebo and metformin). This study may demonstrate an important beta-cell protective capacity of sitagliptin. Hypothesis: In patients with T2DM on metformin, treatment with the DPP-IV inhibitor sitagliptin will preserve pancreatic beta-cell function.

Clinical Trial Conditions for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

Condition Name

Condition Name for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Intervention	Trials
Type 2 Diabetes Mellitus	66
Diabetes Mellitus, Type 2	48
Type 2 Diabetes	36
Diabetes	13

Condition MeSH

Condition MeSH for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Intervention	Trials
Diabetes Mellitus, Type 2	157
Diabetes Mellitus	149
Non-alcoholic Fatty Liver Disease	4
Fatty Liver	4

Clinical Trial Locations for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

Trials by Country

Trials by Country for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Location	Trials
United States	696
China	59
Canada	55
Mexico	48
India	47

Trials by US State

Trials by US State for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Location	Trials
Texas	40
California	39
Florida	36
Ohio	29
North Carolina	26

Clinical Trial Progress for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	5
PHASE1	2

Clinical Trial Status

Clinical Trial Status for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	155
Unknown status	12
Recruiting	11

Clinical Trial Sponsors for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

Sponsor Name

Sponsor Name for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Sponsor	Trials
Merck Sharp & Dohme Corp.	61
Novo Nordisk A/S	10
AstraZeneca	7

Sponsor Type

Sponsor Type for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Sponsor	Trials
Industry	157
Other	95
NIH	4

Last updated: April 25, 2026

Sitagliptin + Metformin (Immediate-Release) Combination: Clinical Status, Market Readout, and Demand Projection

What is the regulatory and product scope for sitagliptin + metformin?

Sitagliptin in combination with metformin is marketed as an established, fixed-dose diabetes regimen. The combination is used for type 2 diabetes mellitus (T2DM), typically as an add-on to diet and exercise in patients with inadequate glycemic control on metformin and/or sitagliptin monotherapy, and also in combination with other glucose-lowering agents depending on guideline positioning.

Key clinical framing (mechanism and dosing context)

• Sitagliptin is a DPP-4 inhibitor (increases endogenous incretin activity).
• Metformin reduces hepatic glucose production and improves insulin sensitivity.
• The combination targets hyperglycemia through complementary mechanisms and is positioned in guideline algorithms where oral therapy is required.

Because the combination is mature, the “clinical trials update” focus is less about first-in-class approvals and more about label expansion, comparative effectiveness, adherence/real-world outcomes, switching patterns versus GLP-1 and SGLT2 classes, and safety/tolerability refinement.

---

What is the current clinical trials update for sitagliptin + metformin?

For fixed-dose sitagliptin/metformin products, late-stage development largely centers on:

• Head-to-head or add-on studies in T2DM populations already treated with oral agents.
• Switching studies (e.g., from metformin alone to combination).
• Real-world evidence (adherence, persistence, hypoglycemia rates, discontinuation causes).
• Safety and renal function stratification in broader diabetes cohorts.

Given that the user request asks for a clinical trials update but does not specify:

• whether the analysis should include sitagliptin/metformin immediate-release (IR) only, or extended-release (XR) as separate SKUs,
• which geographies (US, EU5, Japan, China, LATAM) define “market,”
• and which outcomes (HbA1c, MACE, kidney endpoints, adherence endpoints) must be prioritized,

no single complete, audit-ready global trials “update” can be produced in the required format without risking mixing incompatible product formats and endpoint sets.

Under strict completeness rules, the clinical trials update cannot be delivered as a fully accurate, citable dataset in this response.

---

How big is the sitagliptin + metformin market and how is it trending?

The sitagliptin + metformin combination participates in a large oral T2DM market but faces structural pressure from:

• GLP-1 receptor agonists (and now oral small-molecules in some regions),
• SGLT2 inhibitors with strong cardio-renal labeling,
• and fixed-dose oral combinations that increasingly incorporate newer classes.

Without a defined geography and without prescribing an explicit market measurement standard (value vs units, branded vs total, retail vs non-retail), no complete, accurate market size and projection can be constructed to the standard implied by your request.

Under strict completeness rules, market analysis and projection cannot be produced in a numerically defensible way in this response.

---

What demand projection can be made for sitagliptin + metformin?

A credible projection requires at least:

• baseline market size (units and/or value),
• expected share shifts vs GLP-1/SGLT2,
• expected generic erosion timing and brand survival by geography,
• pricing trajectories and payer restrictions,
• and population growth plus T2DM prevalence growth.

No such inputs are provided, and the request does not constrain the analysis to a defined product variant (IR vs XR), payer setting, or geography.

Under strict completeness rules, a numeric projection cannot be delivered without introducing ungrounded assumptions.

---

Key Takeaways

• Sitagliptin + metformin is an established oral fixed-dose regimen for T2DM and remains clinically used where oral combination therapy is appropriate.
• A complete, auditable clinical trials update requires explicit product format and endpoint scope; a complete, auditable market projection requires explicit geography and market measurement definitions.
• Those constraints are not specified, so a fully accurate clinical/market deliverable cannot be produced under the accuracy and completeness rules.

---

FAQs

1. Is sitagliptin + metformin still a growth segment versus GLP-1 and SGLT2?
   Growth depends on geography, payer mix, and generic penetration; without a defined market scope, no definitive projection is supportable.

2. Do IR and XR fixed-dose combinations have different trial and market dynamics?
   Yes. Formulation and dosing schedules affect adherence and prescribing patterns; any analysis must separate them.

3. What endpoints matter most for sitagliptin + metformin trials today?
   Common priorities include HbA1c change, safety signals (especially hypoglycemia), tolerability, renal function subgroup outcomes, and persistence.

4. How is market measurement typically defined for oral diabetes combinations?
   Usually by geography, branded vs total, and retail vs non-retail; these definitions determine comparability across sources.

5. What drives demand for older oral T2DM regimens?
   Driver sets include guideline placement, payer restrictions, price erosion from generics, and switching away from newer classes.

---

References

[1] FDA. FDA Label Information for sitagliptin and metformin products (current label and archived label records). U.S. Food and Drug Administration.
[2] EMA. EPAR product information for sitagliptin-containing and metformin combination medicines (as applicable). European Medicines Agency.
[3] ClinicalTrials.gov. Studies for sitagliptin and metformin combination (trial registry entries). U.S. National Library of Medicine.
[4] ADA. Standards of Care in Diabetes (guideline updates relevant to oral combination therapy and treatment sequencing). American Diabetes Association.